Reference no: EM133064273
In August 2015, Turing Pharmaceuticals raised the price of Daraprim from $13.30 a tablet to $750, an increase of 5,456 percent (Over and Silverman 2015). Daraprim is the only available treatment for toxoplasmosis, a rare infection that can become deadly for patients with weakened immune systems. This price increase means that an individual's treatment could cost up to $634,000. Daraprim's patent expired in 1953, and it can be compounded for less than a dollar per tablet. (Langreth 2015).
Two contradictory trends are evident. Generic drug prices have been declining in the United States since at least 2010, yet multiple generic drugs have risen in price.(Ornstein and Thomas 2017). The price increases generate far more attention than the price decreases, yet the structure of the market has not changed.
In the United States, pharmaceutical prices (indeed most medical prices) are based on negotiations between private insurers and suppliers. The US market has two features that are uncommon in other countries.. First, pharmacy benefit managers often act as an intermediary between insurers and suppliers. Second, the federal government plays a limited role in negotiating prices. Although the Department of Veterans Affairs negotiates drug prices for its beneficiaries, private firms negotiate for Medicare.
Discussion Questions
-Would you expect demand for Daraprim to be elastic or inelastic? Why?
-What change in the market would make demand for Daraprim more elastic,? Less elastic?
-What would the out-of-pocket cost for Daraprim be for a patient on Medicare? Medicaid?
-What would the price elasticity be after a patient exceeded the out-of-pocket maximum?
-Why did other companies not start making versions of Daraprim?
-Did Turing Pharmaceuticals violate any laws or regulations when it raised the price? Support your response with evidence.
-Could a company have raised the price of a drug like this in Canada, France, Australia? Why? or why not?
-Companies have also raised prices for other off-patent drugs. Can you explain why?
-Can you provide another example of large price increases for off-patent drugs? Provide evidence
-What should the United States do concerning Cases like that of Daraprim?
-Should the Federal government negotiate pharmaceutical prices? Why or Why not?
-Should someone else negotiate pharmaceutical prices? Explain your answer.
|
Calculate the cost per pencil produced in august
: Calculate the cost per pencil produced in August - Determine the cost of goods completed during the month and cost of the WIP inventory on 31March
|
|
Pros and cons of completing stakeholder analysis
: Discuss the pros and cons of completing a stakeholder analysis. Explain why stakeholder analysis is an important step in the action research process
|
|
What is the current recidivism rate in state
: What is the current recidivism rate in your state? What has been the trend in the recidivism rate in your state?
|
|
Respective comparative advantages
: Consider the single-factor production function, Y = AL, for islands A and B. Each island has 100 units of labor (and they cannot move across islands). Island A
|
|
Demand for daraprim to be elastic or inelastic
: In August 2015, Turing Pharmaceuticals raised the price of Daraprim from $13.30 a tablet to $750, an increase of 5,456 percent (Over and Silverman 2015). Darapr
|
|
Moving the maisenbacher house
: What is the role of the City of Springfield in the Maisenbacher case? What are the goals of the city? How will you know if government is effective?
|
|
What is the balance in Utilities Payable as of December
: The company's bank loans ($1,500,000) are all due on June 30, 2023. What is the balance in Utilities Payable as of December 31, 2022
|
|
Short-run cost and the long-run cost
: We are in the fourth Industrial Revolution era which is known as industry 4.0 using big data and artificial intelligent (AI). Like all revolutions, this one has
|
|
Example of libertarian paternalism
: Michael Bloomberg, the mayor of New York City, sought to implement a controversial ban of "super size" sodas in NYC (but did not succeed).
|